• PharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market
  • April 26, 2017 – As previously announced, PharmAthene, Inc. (NYSE MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, have signed a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Today, the companies announced that, pending approval of the merger between the two companies by PharmAthene’s stockholders at a special meeting of PharmAthene’s stockholders scheduled for May 4, 2017, the combined company has been approved for listing on the Nasdaq Global Market under the symbol “ALT.”
  • Altimmune Receives $7.3 Million Contract Modification from BARDA to Fund Manufacturing of its First-In-Class Anthrax Vaccine Candidate NasoShield™
  • March 28, 2017 - Altimmune, Inc., a clinical stage immunotherapeutics company, today announced that the Company was awarded a contract modification to their previously announced contract. Under the U.S. Biomedical Advanced Research and Development Authority (BARDA) contract HHSO100201600008C, Altimmune has been awarded an additional $7.3 million for the manufacturing, scale up and testing of clinical materials to support planned clinical trials of NasoShield™, its first in class anthrax vaccine candidate.
  • ALTIMMUNE TO PRESENT AT THE BIO CEO & INVESTOR CONFERENCE
  • February 6, 2017 – Altimmune, Inc., a clinical stage immunotherapeutics company targeting infectious diseases, announced today that Chief Executive Officer Bill Enright will present at the BIO CEO & Investor Conference on Monday, February 13, 2017 at 4:00 PM ET.
  • PHARMATHENE AND ALTIMMUNE ANNOUNCE MERGER TO CREATE IMMUNOTHERAPEUTICS COMPANY TARGETING INFECTIOUS DISEASES
  • January 19, 2017 - PharmAthene, Inc. (NYSE MKT: PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced today the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction.
  • ALTIMMUNE ANNOUNCES ACCEPTANCE OF HEPTCELL ABSTRACT FOR PRESENTATION AT BSI/NVVI CONGRESS 2016
  • December 6, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that its abstract related to the development of an assay to detect low frequency antigen-specific T cells in HepTcell trial participants was accepted for presentation at the BSI/NVVI Congress 2016 taking place December 6 - 9, 2016 in Liverpool, U.K. HepTcell is Altimmune’s first-in-class T cell-activating immunotherapeutic in development for the treatment of chronic hepatitis B (CHB). A Phase 1 trial is currently underway.
  • ALTIMMUNE TO PRESENT AT THR 28TH ANNUAL PIPER JAFFRAY HEALTHCARE CONFERENCE
  • November 18, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the 28th Annual Piper Jaffray Healthcare Conference to be held November 29 - 30, 2016 in New York, NY. Bill Enright, Chief Executive Officer, is scheduled to present on Wednesday, November 30, 2016 at 1:50 PM ET.
  • ALTIMMUNE ANNOUNCES POSTER PRESENTATION OF HEPTCELL PROGRAM AT 2017 KEYSTONE SYMPOSIA CONFERENCE
  • October 26, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that a poster detailing the design and preclinical evaluation of its HepTcell immunotherapeutic for the treatment of chronic hepatitis B infection will be presented at the 2017 Keystone Symposia Conference taking place October 25 – 29, 2016 in London.
  • ALTIMMUNE ANNOUNCES ADDITION OF CHRISTINE BRENNAN TO BOARD OF DIRECTORS
  • September 13, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that Christine Brennan, PhD, Principal at Novartis Venture Fund, has joined its Board of Directors effective immediately. Dr. Brennan replaces Florent Gros from Novartis Venture Fund.
  • ALTIMMUNE TO PRESENT AT 18TH ANNUAL RODMAN & RENSHAW GLOBAL INVESTMENT CONFERENCE
  • August 30, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the 18th Annual Rodman & Renshaw Global Investment Conference to be held September 11 - 13, 2016 in New York, NY.
  • ALTIMMUNE RECEIVES BARDA CONTRACT OF UP TO $120.2 MILLION TO FUND CLINICAL DEVELOPMENT OF FIRST-IN-CLASS ANTHRAX VACCINE CANDIDATE NASOSHIELD
  • August 1, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that the Company was awarded a contract valued at up to $120.2 million over five years from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to fund the clinical development of NasoShield, its first-in-class anthrax vaccine candidate.
  • ALTIMMUNE TO PRESENT AT CANTOR FITZGERALD’s 2ND ANNUAL HEALTHCARE CONFERENCE
  • July 12, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at Cantor Fitzgerald’s 2nd Annual Healthcare Conference to be held July 12-13, 2016 in New York, NY.
  • ALTIMMUNE TO PARTICIPATE IN TWO UPCOMING CONFERENCES
  • May 3, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be participating in two upcoming industry conferences.
  • ALTIMMUNE ANNOUNCES PARTICIPATION IN VACCINE DEVELOPMENT PANEL AT THE ANNUAL REGIONAL BIOTECH FORUM
  • April 13, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that Bill Enright, Chief Executive Officer, will participate in a vaccine development panel at the Annual Regional Biotech Forum. The panel will take place in Gaithersburg, MD on April 19, 2016 at 9:30 AM ET.
  • ALTIMMUNE EXPANDS CLINICAL DEVELOPMENT TEAM
  • April 05, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced the expansion of its clinical development team. Sybil Tasker, M.D., FACP, FIDSA, was appointed as Senior Vice President, Clinical Research and Development. Dr. Tasker will be responsible for overseeing Altimmune’s clinical research and development programs.
  • AlTIMMUNE TO PRESENT AT TWO UPCOMING CONFERENCES
  • March 01, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that Bill Enright, Chief Executive Officer, will be presenting at the following conferences:

      • 23rd Annual Future Leaders in the Biotech Industry Conference in New York, NY on Friday, March 11, 2016 at 2:00 PM ET
      • 28th Annual ROTH Conference in Orange County, CA on Tuesday, March 15, 2016 at 2:20 PM PT
  • ALTIMMUNE ANNOUNCES PRESENTATION AT BIO CEO & INVESTOR CONFERENCE
  • January 26, 2016 - Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at the BIO CEO & Investor Conference to be held February 8 - 9, 2016 in New York, NY. Bill Enright, Chief Executive Officer of Altimmune, is scheduled to present on Monday, February 8, 2016 at 8:00 a.m. ET.
  • ALTIMMUNE ANNOUNCES PRESENTATION AT BIOTECH SHOWCASE 2016
  • December 21, 2015 – Altimmune, Inc., a clinical stage immunotherapeutic company, today announced that management will be presenting at Biotech Showcase 2016 to be held January 11 – 13, 2016 in San Francisco, CA. Bill Enright, Chief Executive Officer of Altimmune, is scheduled to present on Tuesday January 12, 2016 at 4:45 p.m. PST. The presentation will be held in the Hearst room of the Parc 55 Hotel.
  • ALTIMMUNE CHIEF SCIENTIFIC OFFICER TO PRESENT AT TWO PREMIER VACCINE CONFERENCES
  • October 12, 2015 – Altimmune, Inc., (formerly Vaxin Inc.) a clinical stage immunotherapy and vaccine company, today announced that Chief Scientific Officer M. Scot Roberts, PhD, will present at two premier vaccine conferences in the coming weeks. The first is Bacillus ACT 2015, the international conference on Bacillus anthracis , B. ceres, & B. thuringiensis, to be held later this month in New Delhi, India. The second is Vaccines R&D-2015, presented by the United Scientific Group, which takes place in Baltimore, MD in early November.
  • ALTIMMUNE CEO TO PRESENT AT THE 2015 LADENBURG THALMANN HEALTHCARE CONFERENCE IN NEW YORK CITY
  • September 28, 2015 – Altimmune Inc., (formerly Vaxin Inc.) a clinical stage immunotherapy and vaccine company, today announced that CEO Bill Enright will present at the 2015 Ladenburg Thalmann Healthcare Conference to be held tomorrow at the Sofitel Hotel in New York City. Enright’s presentation will take place at 11:30am ET.
  • VAXIN CHANGES COMPANY NAME TO ALTIMMUNE; MOVE REFLECTS COMPANY'S EXPANSION BEYOND VACCINES TO INCLUDE IMMUNOTHERAPEUTICS
  • September 01, 2015 – Vaxin Inc., a clinical stage immunotherapy and vaccine company, today announced that it has changed its corporate name to Altimmune, Inc. Vaxin was founded in 1997 to pioneer new-generation vaccine technologies and products. Since then, the company has achieved steady success, developing promising vaccine candidates for biodefense and other public health needs, as well as animal health. In a strategic growth move earlier this year, the company acquired UK-based Immune Targeting Systems (ITS) and added prominent new investors to its syndicate.
  • VAXIN FIRST-IN-MAN PHASE I CLINICAL TRIAL INITIATED IN CHRONICALLY INFECTED HEPATITIS B PATIENTS
  • July 27, 2015 – Vaxin Inc., a clinical stage vaccine and immunotherapeutics company, today announced that it has enrolled the first patient into a phase I clinical trial of HepTcell™ (FP-02.2), the company’s immunotherapeutic compound to treat people chronically infected with the hepatitis B virus (HBV). The multicenter trial will be conducted at seven sites within the United Kingdom, and aims to recruit 72 patients with chronic HBV infection.
  • VAXIN STRENGTHENS INTELLECTUAL PROPERTY PORTFOLIO
  • July 21, 2015 – Vaxin Inc. today announced that it has added key patents to its expanding Intellectual Property (IP) portfolio. The clinical stage vaccine and immunotherapeutics company confirmed that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for two patents that protect important elements of its Densigen platform technology for immunotherapeutic treatment of Hepatitis B virus infection, and its RespirVec non-invasive adenoviral vector influenza vaccine.
  • STUDY DEMONSTRATES SUPERIOR PERFORMANCE OF VAXIN’S AdVAV VACCINE FOR PROTECTION AGAINST AEROSOLIZED ANTHRAX
  • April 29, 2015 – Vaxin Inc., a clinical stage vaccine development company, today announced that a recently published study demonstrated that utilizing a single vaccination with the company’s AdVAV™ intranasal anthrax vaccine performs as well as the currently licensed Anthrax Vaccine Absorbed (AVA; BioThrax®), which requires two vaccinations. AdVAV is administered via an intranasal route rather than the intramuscular route of AVA.
  • VAXIN NAMES ELIZABETH ADKINS CZEREPAK AS CHIEF FINANCIAL OFFICER
  • April 13, 2015 – Today, Vaxin strengthened its leadership team by appointing Elizabeth Adkins Czerepak to the newly created position of chief financial officer (CFO). Vaxin develops vaccines for important public health and biodefense needs. Ms. Czerepak is a finance expert with over 20 years of executive experience in the pharmaceutical, biotech, and venture capital industries. As Vaxin’s CFO, she will grow the company’s finance organization, oversee M&A activities, and drive interactions with the investor community.
  • VAXIN CEO TO PRESENT AT FUTURE LEADERS IN THE BIOTECH INDUSTRY CONFERENCE
  • March 17, 2015 – Vaxin, a clinical stage vaccine development company today announced that CEO Bill Enright will present at the Future Leaders in the Biotech Industry Conference this Friday in New York City. Now in its 22nd year, the annual event will be held at the Millennium Broadway Hotel & Conference Center.
  • VAXIN CEO TO JOIN PANEL OF EXPERTS IN DISCUSSION ON NATIONAL BIODEFENSE IMPERATIVES
  • February 23, 2015 – On Tuesday the 24th of February at Texas A&M University, The Blue Ribbon Study Panel on Biodefense will host a Regional Roundtable on national biodefense imperatives. The theme of the day is “The Human/Animal Interface for Biodefense: From Surveillance to Countermeasures”. At the half-day event, Vaxin CEO Bill Enright will join a panel of experts to discuss “Policy Recommendations for Enabling Flexible and Adaptable Development and Manufacturing”.
  • VAXIN ENTERS DEFINITIVE AGREEMENT TO ACQUIRE IMMUNE TARGETING SYSTEMS (ITS); SECURES $16M IN NEW FINANCING Merger of Biotech Pioneers Aims to Accelerate Development of Vaccines for Public Health & Biodefense Needs
  • February 17, 2015 – Moving to advance its leadership in developing vaccines for important public health and biodefense needs, Vaxin Inc. today announced that it has entered into a definitive agreement to acquire Immune Targeting Systems (ITS) Ltd. Vaxin is a clinical stage vaccine development company headquartered in Gaithersburg, Maryland.
  • Vaxin Announces BARDA Exercise of Contract Option Period for its Next Generation Anthrax Vaccine
  • September 25, 2013 - After demonstrated success in Anthrax vaccine development $8.7M of the contract value was awarded in option 1. These funds allow for the conduct of IND-directed studies including additional preclinical pharmacology, continued manufacturing process development, scale-up and GLP safety and toxicology studies.
  • David Brake PhD to Join Vaxin's Board of Directors
  • February 6, 2013 - Dr. Brake has more than 22 years of research and development experience with a record of significant achievements in the biomedical field. He will help provide valuable product development and business insights on animal health vaccine initiatives.
  • Vaxin Announces the Appointment of M. Scot Roberts to Chief Scientific Officer
  • December 3, 2012 - Vaxin Inc., a clinical stage vaccine development company today announced that M. Scot Roberts, PhD has accepted the position as its Chief Scientific Officer. Scot brings a very strong technical background as well as solid knowledge in the business of science.
  • Vaxin Appoints Brigadier General (Ret.) Klaus Schafer to Board of Directors
  • July 10, 2012 - General Schafer has an esteemed military career in medicine, significant programmatic and management experience in biodefense initiatives and in depth knowledge of leading and managing early stage biotechnology companies.
  • Vaxin Receives Phase I SBIR Grant to Evaluate Promising New Anthrax Vaccine
  • June 18, 2012 - This six month grant will allow Vaxin scientists to continue to build our anthrax vaccine portfolio of technologies through the development of novel more effective vaccines against anthrax.
  • Vaxin & Auburn University Receive Million Dollar Grant from Found Animals Foundation to Develop a Vaccine to Sterilize Dogs and Cats
  • June 18, 2012 - Found Animals Foundation's Michelson Prize in Reproductive Biology seeks a low-cost, nonsurgical method to sterilize large populations of cats and dogs and reduce the number of homeless and unwanted animals that are killed each year in shelters. The three-year project draws upon the science of Vaxin’s vaccine technology already tested in humans for influenza and the Scott-Ritchey Research Center’s commitment to develop contraceptive vaccines for companion animals.
  • Vaxin Announces Appointment of Dr. David Drutz Chairman
  • October 13, 2011 - Dr. Drutz has an esteemed career in medicine, significant management and clinical development experience in both pharmaceutical and biotechnology companies as well as successful venture capital experience.
  • Vaxin Awarded BARDA Contract Valued at up to $21.7M to Develop Next Generation Anthrax Vaccine
  • September 16, 2011 - Vaxin was awarded a contract valued at up to $21.7 million by the Office of Biomedical Advanced Research and Development Authority (BARDA) for pre-clinical assessment, final manufacturing process development and the supply of clinical materials to support an IND filing and first-in-man dose ranging study of the company’s proprietary anthrax vaccine, AdVAV.
  • Vaxin Announces Anthrax Vaccine Collaboration Agreement with Stabilitech
  • September 8, 2010 - As a sub-contractor under a recently announced contract with the United States Defense Threat Reduction Agency (DTRA), Stabilitech has been awarded a $4 million contract to stabilize two vaccines using their proprietary vaccine stabilization technology to facilitate the stockpiling of these biodefense vaccines, by protecting them against both heat and freezing damage, and enabling ambient temperature storage.
  • Herbert L. Heyneker, Ph.D., to Join Vaxin's Board of Directors
  • May 4, 2010 - With his impressive scientific and management credentials, the appointment of Dr. Heyneker to its Board of Directors will serve Vaxin in developing and commercializing safe, effective, single-dose, needle-free vaccines.
  • Vaxin Receives Birmingham Business Journal's "Pacesetter" Award
  • April 27, 2010 - Vaxin is recognized as the “Fastest Growing Emerging Company” in the Birmingham area, for outstanding growth rate over the last three years, as well as the company’s continued innovations in vaccine discovery and development.
  • Vaxin Announces Appointments to Board of Directors
  • February 19, 2010 - Lyle A. Hohnke, Ph.D., General Partner, Tullis Dickerson & Company, who will serve as Chairman of the Board, David J. Drutz, M.D., President, Pacific Biopharma Associates; Ike W. Lee, Ph.D., President and Chief Executive Officer, AnC Bio Holdings; and Michael M. Rice, Managing Partner, DJE Advisors.
  • Vaxin Launches Joint Venture with ANC BIO in Korea
  • October 14, 2009 - To develop, manufacture and commercialize Vaxin’s current pipeline of novel vaccines throughout Asia, the Middle East and Oceania. This strategic alliance is expected to produce vaccines against seasonal and pandemic influenza, anthrax and Alzheimer’s disease, as well as other indications.
  • Vaxin Pandemic Vaccine Phase I Release
  • July 17, 2009 - Announced promising initial study data for its lead, intranasal influenza vaccine candidate being developed to protect humans against highly-virulent strains of influenza, including those that could result in a global pandemic. The preliminary data indicate that the vaccine against the H5N1 influenza virus, commonly referred to as “bird flu”, induced strong antibody responses and good tolerability in healthy adults.
  • Vaxin Tech 50 Release
  • June 15, 2009 - Vaxin has been named to Tech Journal South’s 2009 “Tech 50” list, which recognizes the top 50 privately-held technology companies in the southeastern United States. Nominees for the award were judged on several criteria, including technology innovation, management team, marketplace potential and success of execution.
  • Vaxin Completes Dosing of Phase I Human Study of H5N1 Pandemic Flu Vaccine
  • February 24, 2009 -Vaxin has completed dosing of subjects in a Phase I clinical trial of its lead influenza vaccine being developed to protect humans against highly-virulent strains of influenza, including those that could result in a global pandemic.
  • Vaxin Receives $1.4 Million for Anthrax Vaccine Development
  • December 10, 2008 - Awarded from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) under the NIH/NIAID Biodefense Product Development program for the further development of Vaxin’s novel, non-invasive anthrax vaccine. The grant has been issued in conjunction with a contract extension to a Challenge Grant originally awarded to Vaxin in 2005.
  • Vaxin and Crucell Announce Collaboration to Fight Azheimer's Disease
  • November 13, 2008 - Entered into a new strategic collaboration with Dutch biotechnology company, Crucell N.V. to utilize Crucell’s PER.C6® and adenovector technologies for research, development and commercialization of recombinant adenoviral vaccines against Alzheimer’s disease and another undisclosed indication.
  • Vaxin to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
  • November 5, 2008 - Vaxin will present a corporate update at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on Wednesday, November 12, 2008 at 4:30 p.m. Eastern Time.
  • Vaxin Initiates Phase I Human Study of H5N1 Pandemic Flu Vaccine
  • October 8, 2008 - Initiation of its lead influenza vaccine being developed to protect against highly-virulent strains of influenza, including those that could result in a global human pandemic.
  • Vaxin Receives $100,000 Grant for Development of Acne Vaccine
  • September 18, 2008 - Vaxin to develop Acne vaccine in collaboration with The University of California, San Diego School of Medicine (UCSDSM) and the Veteran’s Medical Research Foundation (VMRF). Vaxin has been awarded a grant by the National Institutes of Health (NIH) to support development of a novel vaccine against Propionibacterium acnes (P. acnes), a leading cause of common acne.
  • Vaxin Awarded NIH Funding for Avian Flu Vaccine Development
  • September 10, 2008 - Awarded a $955,357 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to support the ongoing development of the Company’s novel avian influenza vaccine.
  • Vaxin's Pandemic Vaccine Spotlighted
  • August 13, 2008 - Lead vaccine candidate, targeting avian influenza, is being featured today in Boston. Kent Van Kampen, Vaxin’s Chief Operating Officer and a highly respected authority on vaccine development, will be presenting the company’s recent findings.
  • Vaxin Welcomes New CEO
  • August 8, 2008 - As Vaxin has advanced its groundbreaking, needle-free vaccine candidates, the need has grown for additional depth in its executive ranks. The company has addressed that growing need by naming William “Bill” Enright as its new President and Chief Executive Officer.
  • Data from Vaxin’s First Flu Vaccine Clinical Trial Reported in Journal “Vaccine”
  • January 11, 2005 - Safety and Immunogenicity Established for Cell-Culture Manufactured Influenza Vaccine. In a Phase I human clinical study, the company’s recombinant influenza vaccine provides a potential alternative to traditional flu vaccines.
  • Revolutionary Flu Vaccine in Development by Vaxin Inc.
  • October 11, 2004 - In the midst of mounting concerns about shortages of flu vaccine supplies and worries about the deadly avian flu virus and its potential to cause a pandemic, Vaxin Inc., is quietly developing a revolutionary new flu vaccine. The Vaxin influenza vaccine differs from traditional flu vaccines in two important ways: its method of manufacture and its method of delivery; both of which convey potentially significant advantages over traditional flu vaccines.
  • Crucell And Vaxin Announce PER.C6 Licensing Agreement
  • September 13, 2004 - Entered into a license agreement with Dutch biotechnology company Crucell N.V. This non-exclusive license agreement allows Vaxin to use Crucell’s PER.C6® cell line for the development, manufacture and commercialization of its recombinant adenoviral vaccines against certain respiratory viruses.
  • International Vaccine Expert Dr. Alf Lindberg Joins Vaxin Board of Directors - Vaxin Preparing for Flu Vaccine Clinical Trials with Experienced Management Team in Place
  • July 8, 2004 - Vaxin Inc. announced today the appointment of Alf Lindberg, M.D., Ph.D., former Executive Vice President of Research and Development at Aventis Pasteur, to its Board of Directors.
  • World-Renown Vaccinologist to Lead Vaxin
  • March 15, 2004 - One of the world’s leading biotechnology scientists and businessmen, Francis R. Cano, Ph.D., now leads Vaxin Inc., an emerging biotechnology company with a portfolio of vaccines that can be delivered non-invasively. In his new position as chairman of the board and CEO, Cano plans to develop an exciting new flu vaccine and lead the company into a new round of financing.
  • New Hope for Flu Misery
  • February 14, 2004 - As government officials gather to discuss which new flu strains to expect next, others work at a furious pace to prevent flu infections. Vaxin Inc. is developing a nasal-mist influenza vaccine, which could provide a fast, painless vaccine that can be manufactured more rapidly than existing products.
  • Key Patent Issued on Vaxin's Platform Technology
  • March 18, 2002 - First U.S. patent, number 6,348,450 B1, on "Non-Invasive Genetic Immunization, Expression Products Therefrom and Uses Thereof" was issued to Vaxin for non-invasive immunization technology.
  • Anthrax Target of Vaxin’s Vaccine Research
  • October 1, 2001 - Biological warfare has long been a concern of the federal government; Vaxin, Inc. received a grant to develop a vaccine patch to combat anthrax. This disease is so deadly it is 90 percent fatal if treatment is not sought within 24 hours, a natural choice for terrorists. The Small Business Innovation Research grant was awarded by the National Institutes of Health.
  • Navy Awards $3.5 Million to Develop Needleless Vaccination
  • September 14, 2001 - New Vectored Vaccine Laboratory directed by Dr. De-chu Tang at UAB will establish a research laboratory for working on topical vaccine technology, which can revolutionize the way vaccines are given and eliminate the need for needles, syringes and the accompanying pain.
  • Vaxin Receives Grant For Tetanus Vaccine Patch Development
  • June 18, 2001 - Received a grant for $282,625 for research towards developing technology for a vaccine patch for tetanus from the National Institute of Allergy and Infectious Diseases.
  • Vaxin Wins Navy Grant to Develop Vaccine for Dengue Fever
  • June 11, 2001 - The worlds most common mosquito-borne viral disease is the target of a new Navy grant to Vaxin, Inc. The Small Business Innovation Research grant provides $69,700 to develop a DNA needleless vaccine to battle dengue fever, a common ailment that can disable troops sent to tropical locales.
  • Inventor Is Proving No Pain Is Everyone's Gain, Receives International Coulter Award
  • October 11, 2000 - Dr. Tang, vice president and chief technical officer of Vaxin, received the prestigious Coulter Award for Innovation and Entrepreneurship on October 7. The $100,000 award was presented by the Wallace H. Coulter Trust.

    © 2015 Altimmune, Inc.   All rights reserved.   Terms of Use